The Danish Life Science start-up Cytotrack showed international potential Yesterday in Barcelona as a finalist in this years European Venture Contest.

The SEED funded company shared the second place in the competition which has included a total of 576 European contesters from several business sectors. 99 companies were selected for semi-finals and 17 reached the final.

Cytotrack has developed a scanning technology for rare cell detection, which shows superior performance compared to other common technologies. The main application for the technology is in detection of circulating tumor cells. This diagnostic test will help oncologists determine whether a cancer patient is responding to chemo-therapy treatment. More than 50% do not respond and today patients have to wait up to several months before they know. With the Cytotrack technology the information will be available within weeks.

The market for circulating tumor cell detection has the potential to reach €650 million.